Scott N. Boyle - 16 Mar 2022 Form 3 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Business Officer
Signature
/s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
16 Mar 2022
Net transactions value
$0
Form type
3
Filing time
17 Mar 2022, 16:18:42 UTC
Next filing
27 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CCCC Stock Option (Right to Buy) 16 Mar 2022 Common Stock 115,000 $33.23 Direct F1
holding CCCC Performance Restricted Stock Units 16 Mar 2022 Common Stock 26,250 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option shall vest and become exercisable on January 3, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
F2 Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones.

Remarks:

Exhibit 24 - Power of Attorney